Murphy & Mullick Capital Management Corp Buys Shares of 6,162 Novo Nordisk A/S (NYSE:NVO)

Murphy & Mullick Capital Management Corp purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 6,162 shares of the company’s stock, valued at approximately $530,000.

Several other hedge funds also recently modified their holdings of NVO. Potentia Wealth bought a new position in Novo Nordisk A/S during the fourth quarter valued at about $240,000. Zions Bancorporation N.A. increased its holdings in shares of Novo Nordisk A/S by 97.7% during the 4th quarter. Zions Bancorporation N.A. now owns 36,639 shares of the company’s stock valued at $3,152,000 after acquiring an additional 18,104 shares during the last quarter. GQG Partners LLC raised its stake in shares of Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock valued at $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. ICW Investment Advisors LLC lifted its holdings in Novo Nordisk A/S by 1.2% in the 4th quarter. ICW Investment Advisors LLC now owns 41,142 shares of the company’s stock worth $3,539,000 after purchasing an additional 472 shares during the last quarter. Finally, Woodmont Investment Counsel LLC boosted its position in Novo Nordisk A/S by 276.2% during the fourth quarter. Woodmont Investment Counsel LLC now owns 110,551 shares of the company’s stock worth $9,510,000 after purchasing an additional 81,163 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on NVO. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Down 2.3 %

Shares of NVO opened at $73.57 on Wednesday. The stock’s 50-day moving average price is $83.01 and its 200 day moving average price is $99.94. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $330.15 billion, a price-to-earnings ratio of 22.36, a P/E/G ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 12-month low of $73.20 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s payout ratio is 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.